61 results
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd
25 Apr 24
Report of Foreign Private Issuer
4:00pm
for Multidisciplinary Sciences UMG Head of Department Covering discovery and initial characterization of NanoAbs aimed at predefined list of molecular targets. Designed … inhibitors - only moderate - to - severe disease) ▪ Individual preferences Credit: Prof. Michael P. Schön, Department of Dermatology, Venereology
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd
16 Apr 24
Report of Foreign Private Issuer
5:27pm
- Focus of IL - 17 in the pathophysiology of psoriasis and unmet medical need – 5th DDDS Europe, April 17, 2024 Michael P. Schön Department … or Medicine Professor Dr Matthias Dobbelstein Fellow at Max Planck Institute for Multidisciplinary Sciences UMG Head of Department Covering discovery
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd
18 Jan 24
Report of Foreign Private Issuer
11:50am
Dobbelstein Fellow at Max Planck Institute for Multidisciplinary Sciences UMG Head of Department Covering discovery and initial characterization of NanoAbs … including pivotal Phase 3. PhD from Department of Immunology, Weizmann Institute of Science . ELAD MARK – COO Led scale - up, tech transfer, manufacturing
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd
9 Jan 24
Report of Foreign Private Issuer
8:45am
Dobbelstein Fellow at Max Planck Institute for Multidisciplinary Sciences UMG Head of Department Covering discovery and initial characterization of NanoAbs … from Department of Immunology, Weizmann Institute of Science . ELAD MARK – COO Led scale - up, tech transfer, manufacturing of recombinant proteins
6-K
EX-1.1
SCNI
Scinai Immunotherapeutics Ltd
19 Sep 23
Report of Foreign Private Issuer
3:06pm
Assets Control of the U.S. Treasury Department (“OFAC”).
(ll) U.S. Real Property Holding Corporation. The Company is not and has never been a U.S. real
6-K
EX-99.1
02ii2qv5j zln
23 Aug 23
Report of Foreign Private Issuer
6:10am
6-K
EX-99.1
r1rrj0 vncxo07874i13
5 Jul 23
Report of Foreign Private Issuer
9:28am
8-K
EX-99.1
57fbw5 ucpdjt14
4 May 23
Regulation FD Disclosure
9:25am
8-K
xgdaw1jkit1hvyi
4 May 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
10-K
sg3k6rv928 gy95
17 Apr 23
Annual report
4:06pm
6-K
EX-99.1
4mqqqlonojb04tfp
29 Dec 22
Report of Foreign Private Issuer
10:39am
6-K
EX-1.1
iv8v06i
20 Dec 22
BiondVax Announces Closing of $8 Million Underwritten Public Offering
5:29pm
F-1/A
EX-1.1
ymzep
14 Dec 22
Registration statement (foreign) (amended)
4:45pm
F-1/A
EX-10.14
l6a0qd97
14 Dec 22
Registration statement (foreign) (amended)
4:45pm
6-K
EX-99.1
fp8y4
10 Nov 22
Current Report
5:28pm
F-1
EX-10.14
o5q1gn
29 Sep 22
Registration statement (foreign)
9:22am
6-K
EX-99.1
umu000jcr53ymh u0zrx
11 Jan 22
Report of Foreign Private Issuer
6:06am